论文部分内容阅读
目的研究依达拉奉对急性脑梗死患者血清基质金属蛋白酶9(MMP-9)及肿瘤坏死因子α(TNF-α)的影响。方法选择发病3天内的脑梗死患者,随机分为依达拉奉治疗组(50例)和常规治疗组(50例),另选健康对照组(30例)。采用酶联免疫吸附试验(ELISA)于治疗前、治疗后14天抽血检测脑梗死患者血清MMP-9、TNF-α水平,健康对照组抽血检测1次。结果脑梗死患者血清MMP-9、TNF-α水平治疗前后均较健康对照组明显增高(P<0.05),依达拉奉组在治疗后血清MMP-9、TNF-α水平较常规治疗组降低(P<0.05)。结论 MMP-9、TNF-α与脑梗死发病密切相关,依达拉奉可降低脑梗死患者血清MMP-9、TNF-α水平,具有减轻炎症反应和脑保护作用。
Objective To investigate the effect of edaravone on serum matrix metalloproteinase 9 (MMP-9) and tumor necrosis factor α (TNF-α) in patients with acute cerebral infarction. Methods Patients with cerebral infarction within 3 days after onset were randomly divided into edaravone treatment group (50 cases) and conventional treatment group (50 cases), and healthy control group (30 cases). Serum levels of MMP-9 and TNF-α in patients with cerebral infarction were measured by enzyme-linked immunosorbent assay (ELISA) before treatment and 14 days after treatment. Blood samples were collected from healthy controls. Results Serum levels of MMP-9 and TNF-α in patients with cerebral infarction were significantly higher than those in healthy controls before and after treatment (P <0.05). The levels of serum MMP-9 and TNF-α in edaravone group were lower than those in normal control group (P <0.05). Conclusions MMP-9 and TNF-α are closely related to the pathogenesis of cerebral infarction. Edaravone can reduce the serum levels of MMP-9 and TNF-α in patients with cerebral infarction and reduce the inflammatory reaction and brain protection.